Boston Scientific (BSX) Stock Buyback History
TTM buyback yield N/A.
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
5.5%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
N/A
5Y CAGR of spend
-100.0%
Peak year (2005)
$734.00M
Cumulative spend
$4.77B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Diluted share count is up 5.5% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $299.00M | −$299.00M | 1.49B | 0.6% | — |
| 2024 | $0.00 | $266.00M | −$266.00M | 1.49B | 1.5% | — |
| 2023 | $0.00 | $233.00M | −$233.00M | 1.46B | 1.7% | — |
| 2022 | $136.00M | $220.00M | −$84.00M | 1.44B | 0.4% | 0.21% |
| 2021 | $0.00 | $194.00M | −$194.00M | 1.43B | 1.2% | — |
| 2020 | $535.00M | $170.00M | $365.00M | 1.42B | 0.4% | 1.04% |
| 2019 | $0.00 | $157.00M | −$157.00M | 1.41B | 0.7% | — |
| 2018 | $0.00 | $140.00M | −$140.00M | 1.40B | 0.6% | — |
| 2017 | $0.00 | $127.00M | −$127.00M | 1.39B | 1.1% | — |
| 2016 | $0.00 | $116.00M | −$116.00M | 1.38B | 2.7% | — |
| 2015 | $0.00 | $107.00M | −$107.00M | 1.34B | -0.5% | — |
| 2014 | $125.00M | $103.00M | $22.00M | 1.35B | 0.5% | 0.71% |
| 2013 | $500.00M | $105.00M | $395.00M | 1.34B | -4.7% | 3.13% |
| 2012 | $600.00M | $108.00M | $492.00M | 1.41B | -7.4% | 7.67% |
| 2011 | $492.00M | $128.00M | $364.00M | 1.52B | 0.1% | 6.38% |
| 2010 | $0.00 | $150.00M | −$150.00M | 1.52B | 0.7% | — |
| 2009 | $0.00 | $144.00M | −$144.00M | 1.51B | 0.6% | — |
| 2008 | $0.00 | $138.00M | −$138.00M | 1.50B | 0.8% | — |
| 2007 | $60.00M | $122.00M | −$62.00M | 1.49B | 16.7% | 0.35% |
| 2006 | $0.00 | $0.00 | $0.00 | 1.27B | 52.1% | — |
| 2005 | $734.00M | $0.00 | $734.00M | 0.84B | -2.2% | 3.61% |
| 2004 | $360.00M | $0.00 | $360.00M | 0.86B | 1.6% | 1.22% |
| 2003 | $570.00M | $0.00 | $570.00M | 0.84B | 1.7% | 1.84% |
| 2002 | $0.00 | $0.00 | $0.00 | 0.83B | -0.2% | — |
| 2001 | $0.00 | $0.00 | $0.00 | 0.83B | 1.3% | — |
| 2000 | $222.00M | $0.00 | $222.00M | 0.82B | -0.6% | — |
| 1999 | $127.00M | $0.00 | $127.00M | 0.82B | 6.2% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.78B | -2.9% | — |
| 1997 | $187.00M | $0.00 | $187.00M | 0.80B | 0.5% | — |
| 1996 | $63.80M | $0.00 | $63.80M | 0.80B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $57.40M | $0.00 | $57.40M | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Boston Scientific (BSX) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Boston Scientific (BSX)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Boston Scientific (BSX)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | — | $0 | ||
| 2024 | $0 | — | $0 | ||
| 2023 | $0 | -100.0% | -$136.00M | ||
| 2022 | $136.00M | — | +$136.00M | ||
| 2021 | $0 | -100.0% | -$535.00M | ||
| 2020 | $535.00M | — | +$535.00M | ||
| 2019 | $0 | — | $0 | ||
| 2018 | $0 | — | $0 | ||
| 2017 | $0 | — | $0 | ||
| 2016 | $0 | — | $0 | ||
| 2015 | $0 | -100.0% | -$125.00M | ||
| 2014 | $125.00M | -75.0% | -$375.00M | ||
| 2013 | $500.00M | -16.7% | -$100.00M | ||
| 2012 | $600.00M | +22.0% | +$108.00M | ||
| 2011 | $492.00M | — | +$492.00M | ||
| 2010 | $0 | — | $0 | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | -100.0% | -$60.00M | ||
| 2007 | $60.00M | — | +$60.00M | ||
| 2006 | $0 | -100.0% | -$734.00M | ||
| 2005 | $734.00M | +103.9% | +$374.00M | ||
| 2004 | $360.00M | -36.8% | -$210.00M | ||
| 2003 | $570.00M | — | +$570.00M | ||
| 2002 | $0 | — | $0 | ||
| 2001 | $0 | -100.0% | -$222.00M | ||
| 2000 | $222.00M | +74.8% | +$95.00M | ||
| 1999 | $127.00M | — | +$127.00M | ||
| 1998 | $0 | -100.0% | -$187.00M | ||
| 1997 | $187.00M | +193.1% | +$123.20M | ||
| 1996 | $63.80M | — | +$63.80M | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | -100.0% | -$57.40M | ||
| 1993 | $57.40M | — | +$57.40M | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | — |
Boston Scientific (BSX) most recent annual buyback spend stands at $0 (2025).
Across 2020–2025 (5 years), Boston Scientific buyback spend produced a CAGR of -100.0% – with a net decline across the window.
Between 2005 and 2025, Boston Scientific buyback spend plunged 100.0%, falling from $734.00M to $0.
The dataset's maximum buyback spend sits at $734.00M (2005); the minimum reading of $0 dates to 1991.
Among 8 Healthcare peers, Boston Scientific (BSX) ranks 8th; the peer median for buyback spend is $2.75B.
Boston Scientific Buyback Spend 2025: $0
Boston Scientific buyback spend in 2025 was $0.
Boston Scientific Buyback Spend 2024: $0
Boston Scientific buyback spend in 2024 was $0.
Boston Scientific Buyback Spend 2023: $0
Boston Scientific buyback spend in 2023 was $0, plunged 100.0% below 2022.
Boston Scientific Buyback Spend 2022: $136.00M
Boston Scientific buyback spend in 2022 was $136.00M.
Boston Scientific Buyback Spend 2021: $0
Boston Scientific buyback spend in 2021 was $0.
See more financial history for Boston Scientific (BSX).
Sector peers by buyback spend
Companies in the same sector as Boston Scientific, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Boston Scientific splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.44B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Boston Scientific's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Boston Scientific buy back its own stock?
Yes, Boston Scientific (BSX) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Boston Scientific diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Boston Scientific's share count changed?
Diluted weighted average shares changed by about 5.5% over roughly five fiscal years (annual income statement data).
What is Boston Scientific's buyback spend?
Latest reported buyback spend for Boston Scientific (BSX) is $0 (period ending March 31, 2026).
What is the long-term growth rate of Boston Scientific buyback spend?
Boston Scientific (BSX) buyback spend compound annual growth rate is -100.0% over the most recent 5 years available.
When did Boston Scientific buyback spend hit its highest annual value?
Boston Scientific buyback spend reached its highest annual value of $734.00M in 2005.
What was Boston Scientific buyback spend in 2024?
Boston Scientific (BSX) buyback spend in 2024 was $0.
What was Boston Scientific buyback spend in 2025?
Boston Scientific (BSX) buyback spend in 2025 was $0.
Explore more
BSX Overview
Company profile, financial tools, and key metrics
BSX Revenue Counter
Earns $653.70 every second. See per minute, hour, and day.
BSX Earnings Counter
Earns $112.66 per second net profit. See per minute, hour, and day.
BSX Economic Scale
Exceeds Niger's GDP. Compare with world economies.
BSX What If Invested
What if you had invested $1,000? See historical returns from any date.
BSX How It Makes Money
Discover visual breakdown of $20.61B in revenue — where it comes from and where it goes.
BSX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BSX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BSX Daily Price Character
Balanced · 48.8% historical win rate (green days). Streaks & record days.
BSX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
BSX Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.